An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2013
At a glance
- Drugs TAK 128 (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions
- Sponsors Takeda Global Research and Development Center
- 18 Dec 2008 Planned number of patients added to 221.
- 07 Oct 2008 New trial record.